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Abstract
Background: Novel diagnostic triage and testing strategies to support early detection of cancer could improve
clinical outcomes. Most apparently promising diagnostic tests ultimately fail because of inadequate performance in
real-world, low prevalence populations such as primary care or general community populations. They should therefore
be systematically evaluated before implementation to determine whether they lead to earlier detection, are cost-
effective, and improve patient safety and quality of care, while minimising over-investigation and over-diagnosis.
Methods: We performed a systematic scoping review of frameworks for the evaluation of tests and diagnostic approaches.
Results:We identified 16 frameworks: none addressed the entire continuum from test development to impact on
diagnosis and patient outcomes in the intended population, nor the way in which tests may be used for triage
purposes as part of a wider diagnostic strategy. Informed by these findings, we developed a new framework, the
‘CanTest Framework’, which proposes five iterative research phases forming a clear translational pathway from new test
development to health system implementation and evaluation.
Conclusion: This framework is suitable for testing in low prevalence populations, where tests are often applied for triage
testing and incorporated into a wider diagnostic strategy. It has relevance for a wide range of stakeholders including
patients, policymakers, purchasers, healthcare providers and industry.
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Background
Diagnosing cancer early is a public and policy priority,
with primary care the preferred setting for this to occur
[1]. This has led to a desire for better tests for early
detection of cancer, ideally ones useable in primary care.
However, sustained and substantial investment in the
development of novel biomarkers and other tests has
mainly benefited prognostication and surveillance of
patients already diagnosed with the disease [2]. In
contrast, there have been few benefits in improving the
precision and timeliness of diagnosis of cancer in cancer
patients who generally present to primary care with
symptoms [3]. A wider range of better tests could be
transformational [4]. This ‘grand challenge’ of improving
early cancer diagnosis has been recognised by a wide
range of stakeholders including policymakers, purchasers,
health care providers and consumers, and industry.
While advances in technology are producing a growing
array of new diagnostics involving biomarkers, sensors,
imaging devices and artificial intelligence algorithms [5],
the vast majority of apparently promising cancer diag-
nostic tests in early development fail because they do
not perform adequately in the low prevalence popu-
lations in which they will eventually be applied [6], the
so-called ‘spectrum effect’. Thus, a test developed in a
population with a higher prevalence of disease (or at
higher risk) will typically have a lower sensitivity and
higher specificity when applied in a population with
lower disease prevalence (or at lower risk) [6]. This leads
to high rates of false positive tests, and increasing re-
ferrals to specialist care, such as symptomatic women
with raised CA125. Alternatively, a test may be marketed
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too soon and be inappropriately applied – the implemen-
tation of Prostate Specific Antigen (PSA) testing at popu-
lation level, even before results of screening trials were
available, is a well-known example [7]. Thus, the chal-
lenges of evaluating tests for cancer and other low-
prevalence conditions include potential over-investigation
and over-diagnosis, deciding on the reference standards to
be used in assessing test accuracy, and outcomes relevant
to patients.
Rigorous evaluation of new tests has been undertaken
across a range of medical disciplines such as biochemis-
try, pathology, radiology and genomics, informed by
frameworks developed by academic or policy groups at
national or international levels. These frameworks apply
at various stages in the diagnostic pathway from early
development to implementation. They aim to guide a
variety of stakeholders, including test developers, clini-
cians, researchers and policy makers, on what evidence
is needed at each stage of development of a test ‘from
bench to community’.
The last review of diagnostic test frameworks, published
in 2009, identified several common phases of test eva-
luation: technical efficacy, clinical accuracy, comparative
accuracy, diagnostic and therapeutic impact, patient
outcomes, and societal aspects [8]. Most frameworks
described only parts of the diagnostic evaluation
process but many failed to consider issues specific to
populations with a low prevalence for the condition
of interest.
We aimed to address this. Specifically, we were inter-
ested in frameworks with explicit recognition of:
(i) the prevalence of cancer in the studied population
and potential impact of spectrum bias [6];
(ii) the application of a test as a triage test rather than
a diagnostic test to raise post-test probability of
cancer to inform subsequent decision making and
definitive testing; and
(iii) the incorporation of a test into a broader diagnostic
strategy i.e. involving either more than one test
undertaken concurrently or sequentially, or
integrated into a more complex approach using
the test result combined with other data
(e.g. demographics, symptoms, simple
measurements such as BMI, and other tests)
within the evaluation framework.
We call these ‘essential criteria’ from now on.
Methods
Systematic scoping review
We undertook a systematic scoping review to examine
prior theoretical frameworks using the Arksey and
O’Malley six-stage methodological framework, enhanced
by more recent recommendations (see Fig. 1) [9, 10].
Our search strategy was initially based on Lijmer et al’s
search terms [8]. We conducted searches for literature
published from January 2009 to August 2017 in Medline,
Embase and Web of Science (n = 592), and asked the
consensus group to identify relevant frameworks and
authors active in the field of diagnostic test evaluation.
We combined the results to form a body of literature,
further investigated using retrospective and prospective
snowball methods, to search reference lists of framework
papers published since the Lijmer et al. review, and cita-
tions of framework papers and authors’ papers published
in the past 10 years (n = 9552). We then selected for
inclusion, models or frameworks for the evaluation of
medical tests, at any stage in the diagnostic pathway,
published in a peer-reviewed journal, and in the English
language (n = 47 for full-text review).
We included 16 frameworks (see Table 1 and
Additional file 1: Table S1). The included frame-
works focused on generic frameworks for diagnostic
tests (n = 8) [11–18]; frameworks specific to the evaluation
of genetic tests (n = 6) [5, 19–23]; a framework addressing
issues of diagnostic safety and the use of the test within
the context of the patient-doctor consultation (n = 1) [24];
and on value proposition of testing (n = 1) [25]. They were
mostly developed by authors in North America, and fre-
quently referenced Fryback & Thornbury’s original frame-
work paper, the Hierarchical Model of Efficacy, published
in 1991 [11]; many of the subsequent frameworks describe
similar phases of research to demonstrate these levels of
evidence. We reviewed these preliminary findings at an
international consensus meeting, held in London, October
2017, and were unable to identify a single framework that
recognized the three essential criteria. Specifically, the
limitations of existing frameworks were: usually focusing
on a single test rather than a series of tests or a compa-
rator test; not recognising that some tests can be used to
raise post-test probability of cancer to inform selection for
subsequent definitive diagnostic testing i.e. use as a triage
test, and; mostly not accounting for incorporation of the
test into a diagnostic strategy.
Synthesis and development of the CanTest framework
Although no framework fully met our requirements, the
consensus group agreed that the Lin et al model mapped
most closely to our aims [23]. However, it omitted key
aspects of incorporation of a test into a testing strategy,
and the usage of a test for triage. Furthermore, most of
the frameworks were too simplistic, and ignored non-
linearity in development, that is, the need for iteration
back and forth between phases of research. Horvath et al’s
Test Evaluation Framework, [17] and Thompson et al’s
model incorporating multiple test attributes [18], were
among the few which recognised the iterative or cyclical
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nature of test evaluation and interplay between different
phases of evaluation. The SaferDx framework was the only
one to deal in detail with the interplay of the test’s per-
formance and the provider interpretation within the wider
context of the patient’s diagnostic process, as well as inter-
actions between various components of the diagnostic
work system distributed in space and time [24]. SaferDx
also made explicit the role of the test in triage of patients
for possible additional testing and speciality referral.
Finally, SaferDx recognised the need to coordinate the
diagnostic process (often involving performance and inter-
pretation of different tests at different times and locations)
and to ensure fail-safe patient follow-up.
As no existing framework was satisfactory, the consen-
sus group developed the CanTest Framework, informed
by these key papers, and refined by further iterative
discussion and consensus within the multidisciplinary
group. We aimed to develop a new comprehensive,
methodological framework that addressed the continuum
from development of the test to impact on diagnosis and
patient outcomes in routine practice, for use by test
developers, including industry, research funders and
academics. We specifically aimed to incorporate: a shift
in focus away from a single test towards evaluation of
its integration into a diagnostic strategy; greater clarity
around the changes in test performance from highly
selected populations towards the final intended, lower
prevalence population; and the iterative nature of test
evaluation and development.
Results
Figure 2a depicts the core elements of the CanTest
Framework. The consensus group chose to focus on the
translational pathway of tests for which there was already
preliminary evidence of analytic validity [26]. Importantly,
the CanTest Framework is cyclical, reflecting the iterative
Fig. 1 Flow Diagram for systematic scoping review
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Fig. 2 a The CanTest Framework. b The CanTest Framework - Design and Methods
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nature of translational research and how failure to estab-
lish important developmental steps returns the test eva-
luation to a previous phase, and potential redesign of the
test, as well as forward to the next phase.
The CanTest Framework consists of two elements.
The upper part of the figure depicts the five phases that
a new test ideally should follow (whether ‘pushed’ by
patient and public demand or technological development,
or ‘pulled’ by clinical need) before implementation into
routine practice. The lower part of the figure outlines the
changes that occur during these phases in the popula-
tion/setting, the test and its incorporation into a diag-
nostic strategy, the test comparators, and the outcomes
measured (the so-called ‘PICO’ elements summarising
‘population, intervention, comparator and outcomes’).
Across the framework key issues of bias and generalisabi-
lity are relevant to the overall clinical validity of a new test.
This includes, for example, potential overfitting of data in
Phase 1, bias due to known and unknown differences
between comparator groups, and bias due to retrospective
designs [27]. Spectrum bias, an issue of generalisability, is
also critical across the framework, hence the explicit con-
sideration of study population, disease prevalence and the
final intended population in which the test will be used.
Phase 1- Selection of test and initial measures of
single test performance, typically occurring at the start
of test evaluation. It includes measures of analytic vali-
dity, diagnostic accuracy, and often some technical refine-
ment of the test. At this stage, the test is evaluated in a
highly selected population in ‘proof of principle’ studies,
against a reference or gold standard, and focusses ex-
clusively on comparative performance of that individual
test to a reference standard.
Phase 2- Measures of clinical test performance, pro-
vides information on diagnostic accuracy, and the feasibil-
ity of performing the test in intended populations and
settings (such as staffing needs, sampling, processing). In
addition, it provides further evidence about analytic valid-
ity and test reproducibility in the intended settings. At this
phase, tests are still evaluated in relatively selected popula-
tions and therefore with a higher prevalence of cancer
than in the final intended population. The test is again
likely to be evaluated alongside, and in comparison to, a
reference standard in potentially several comparative
accuracy studies, of increasing generalisability.
Phase 3- Impact on clinical decision-making and
health outcomes, provides information on diagnostic
accuracy in intended populations, and begins to examine
measures of clinical utility focusing on the impact of the
test on clinicians and patients. This includes acceptabil-
ity and feasibility of the test from both perspectives, its
impact on clinical decision-making, diagnostic triage and
incorporation into diagnostic strategies. By this phase,
the population in which the test is being evaluated is
becoming more similar to the final intended population,
and the test may be evaluated as part of a combination
of tests. The reference standard to which the test is
being compared may now have changed to usual care
rather than an ideal or perfect gold standard in compara-
tive accuracy studies. Outcomes are no longer restricted
to test performance, but rather also include those related
to clinical decision-making and patient experience, inclu-
ding quantifying benefits and harms.
Phase 4- Effectiveness of new diagnostic strategy
on clinical outcomes, evaluates the effectiveness and
cost-effectiveness of the new diagnostic strategy com-
pared to existing strategy(s). The key changes are the
test is now being evaluated in the population in which it
is intended to be used, and it is more likely to be eva-
luated as part of a combination of tests or test strategies.
The comparison is now firmly with usual care testing
processes, and the outcomes measured are those of
clinical and cost-effectiveness.
Ideally, tests should only be implemented following
Phase 4 evaluations, but pre-implementation assessment
can occur from Phase 3 and, even after adoption into
routine practice, a further phase of post-implementation
evaluation is important.
Phase 5- Implementation and effects at health care
system and population level. Post-implementation
surveillance should determine effects on the health care
system, including use of the test beyond the intended
population, referral patterns and costs, as well as effects at
the population level such as stage at diagnosis, survival
and inequalities in the use of diagnostic care and relevant
clinical outcomes. At this stage, the test or diagnostic
strategy is often evaluated using routine observational data
or qualitative studies.
Figure 2b has been included as it complements the
CanTest Framework with additional guidance on research
design and methods most appropriate for each phase of
evaluation of a test or diagnostic strategy. Small-scale effi-
cacy trials have a role from Phase 3 moving towards larger
pragmatic randomised controlled trials in phase 4. These
would be complemented by other research methods, such
as qualitative approaches, health economic modelling
and impact studies, and natural experiments arising
from premature implementation.
Discussion
Diagnostic test studies generally focus on accuracy, often
in a population already diagnosed with cancer, yet a clear
translational pathway from new test development to
health system implementation requires a wider assess-
ment of their value and impact on patients and the
healthcare system, including cost-effectiveness, crucially
in the population for which the test is intended [16].
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Without a more efficient (or clearly laid out) pathway,
there is a risk that the pathway to implementation is not
only slow but also unattractive to investors and research
funders. Indeed, a recent review of new diagnostic tests
in primary care settings showed that the median time to
complete the ‘invention to implementation’ cycle was 9
years (IQR 6–13 years) [28]. A series of papers published
in 2017 on decision-making about healthcare-related
tests and diagnostic test strategies started with the
acknowledgement that ‘surprisingly little progress has
been made’ [29].
Methodological frameworks are needed to guide diag-
nostic test evaluation and inform stakeholders about what
evidence should be sought to justify implementation. They
can be of particular value in areas of uncertainty or high
complexity, or where there are differing opinions between
stakeholders. We identified specific needs relating to the
evaluation of cancer diagnostic tests in low prevalence
populations where spectrum bias becomes more impor-
tant; and where tests are used for triage and incorporated
into a diagnostic strategy. While the framework has been
developed for cancer detection research, its principles are
generic and applicable not only to cancer but also to many
other low prevalence conditions.
The framework makes explicit not only what is being
evaluated at each phase, but crucially, what is changing in
the PICO elements at each of these phases. Test eva-
luation may be iterative and the results of one phase may
lead test designers back to earlier phases and redesign of
the test. Patients are at the heart of this framework, from
driving the research agenda and the push for new tests,
via careful evaluation of patient-centred outcomes inclu-
ding acceptability, harms and benefits in phase 3, to the
evaluation of population outcomes including inequalities,
stage shift and survival post-implementation in Phase 5.
All these points are strengths.
While the framework encompasses a series of neces-
sary phases, in reality tests may be implemented before
evidence exists from Phase 3 and 4 studies, leaving
Phase 5 research as the only option. The sample sizes re-
quired to show whether detecting low prevalence disease
improves patient outcomes (Phase 3 and above) are large
and may not be feasible; indeed, modelling studies rather
than empirical evaluation may be the only possibility.
This may be the case, for example, where a new test is
more accurate than an existing test.
Some phases of the framework may require expansion
over time: in Phase 3, although we had patient input to the
consensus, it is unclear which components or outcomes of
test evaluation are most important to patients themselves.
This deficit has been recognised by the US-based Patient-
Centred Outcomes Research Institute and other groups,
and is an area of current research [30]. In Phase 5, we refer
to evaluating utilisation of the test across the healthcare
system; this implies a focus on implementation research
methods and evaluation of effects on workflow, staffing and
logistics, which are vital for test sustainability.
A key question with any proposed new framework is
‘How could or should it be used?’ [18]. The CanTest
Framework helps map current evidence about a test, and
where that sits along the Phases of test evaluation. This
supports decisions about the next critical research ques-
tions and future study designs. Examples of cancer de-
tection tests in low prevalence populations to which
application of the CanTest Framework would be useful
have been illustrated in Table 2 and include:
(i) existing tests transferred to primary care,
or to point-of-care, for detecting specific
cancers among defined groups in primary
care populations, including those with and
without symptoms (e.g. Faecal Immunochemical
Testing for colorectal cancer);
(ii) existing tests currently only accessible in secondary
care being made more available to primary care
practitioners (e.g. CT or MRI scans);
(iii)novel tests with potential relevance for primary
care, such as the Stockholm-3 model for prostate
cancer detection [31], or the CancerSEEK bio-
marker panel [32].
The CanTest Framework acknowledges the need to ad-
dress cognitive and cultural factors influencing decision-
making about diagnostic testing during the medical
consultation, coordination of the diagnostic process
(often involving performance and interpretation of dif-
ferent tests at different times and locations), and fail-safe
patient follow-up [3, 23, 33]. These are all critical to
research in Phases 3–5 to understand how tests are in-
corporated into diagnostic strategies and how they are
implemented into routine practice.
This new framework has relevance for a wide range of
stakeholders. Diagnostic test developers have traditionally
focused on the earlier phases of research examining ana-
lytical accuracy and preliminary evidence of performance
characteristics [15], while health services researchers have
focused on studies of effectiveness and implementation in
various clinical settings. Researchers from these different
perspectives will find that the framework guides their
research and design strategies and choice of outcomes. It
may also promote collaboration across researcher ‘silos’ to
promote speedier translation of promising tests from
bench to clinic.
Diagnostic test developers are at the vanguard of
technological advances, producing a growing array of new
medical diagnostics [34]. However, they often find that
return on investment for new tests is low, and there may
be little commercial incentive to support clinical testing
Walter et al. BMC Cancer          (2019) 19:586 Page 7 of 11
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beyond requirements for regulatory approval. We
anticipate that the CanTest Framework can promote
collaboration and partnership between industry, aca-
demia and healthcare providers to undertake phased
evaluation, aiming to deliver a product whose benefits
outweigh its harms. Furthermore, it will be useful to
facilitate a shared language for communication be-
tween test developers and clinicians about what evi-
dence is needed before considering promoting it for
routine clinical use. It may be particularly useful to
better inform or combat speculative media reports of
early stage biomarker research like ‘a promising new
test to detect cancer early’ [32], when the framework
will demonstrate that a test may only be in an early
phase of evidence gathering.
Clinicians need trustworthy evidence about the
value of a test, as well as information as to how it fits
best into diagnostic strategies and approaches in daily
practice, its role in decision-making and triage, and
its effects on patient safety [16]. Patients may assume
that all cancer testing is inherently beneficial, without
being aware of the potential harms from false positive
results, over-detection of slow-growing cancers and
subsequent overtreatment. Generating evidence that
patients can use with their clinicians, to weigh up the
potential harms and benefits of a tests is highly
valuable [30].
Policy makers also may feel pressure from various
groups to approve, or reimburse, new tests, particularly in
areas such as cancer that are often in the public eye. The
framework provides a way that policy makers and health
technology assessment groups can use to assess how far
along the development to implementation pathway a new
test is, and guide deployment decisions. Finally, funders
have traditionally struggled to encourage collaborations
between academic and commercial groups. Adopting
the CanTest Framework would enable funding bodies
(and also test developers) to specify exactly where and
how they wish to drive the early detection and diagno-
sis research agenda.
Conclusion
A robust conceptual approach to development, imple-
mentation and evaluation of cancer diagnostic tests
would ensure that they are fit for purpose when in-
troduced into clinical practice. Because no suitable
framework is currently available, we developed the
CanTest Framework to address this gap, proposing
that this will help to overcome methodological and
practical challenges to improve decision making and
patient outcomes related to diagnostic tests [35]. The
new framework presents an advance that addresses
specifically the evaluation of cancer diagnostic tests
along the continuum from test development to rou-
tine use in the intended population. Although focused
specifically on cancer diagnostics, it is applicable to
the development and evaluation of many diagnostic
and screening tests which are intended for use in low
prevalence populations.
Additional file
Additional file 1: Table S1. Included Frameworks. (DOCX 35 kb)
Abbreviations
BMI: Body Mass Index; CA125: Cancer Antigen 125; CT: Computed
tomography; IQR: InterQuartile Range; MRI: Magnetic resonance imaging;
PSA: Prostate Specific Antigen; UK: United Kingdom; US: United States
Acknowledgements
We thank members of the CanTest External Stakeholders Group for early
discussions around this study and framework development: Prof Stephen
Taplin, Prof Richard Hobbs, Archbishop Douglas Lewins, Dr. Imran Rafi.
Authors’ contributions
FW, MT and JE led the conceptualisation and design of the study. IW
performed the searches. FW, IW, MT and JE interpreted the analyses, and GA,
WH, MJ, GL, MM, RN, GR, HS, AS, SS and PV contributed to interpretation of
the analyses. FW wrote the paper, with JE and MT. IW, GA, WH, MJ, GL, MM,
RN, GR, HS, AS, SS and PV reviewed and commented on the manuscript and
have approved the final version. FW is guarantor.
Funding
This research arises from the CanTest Collaborative, which is funded by
Cancer Research UK [C8640/A23385]. The funder has had no role in the
study, writing of the report, or decision to submit the paper for publication.
FW was supported by an NIHR Clinician Scientist award. GL is supported by
a Cancer Research UK award (Advanced Clinician Scientist Fellowship
C18081/A18180). JE is funded by an NHMRC Practitioner Fellowship. RN and
MM are supported by the National Institute for Health Research (NIHR)
infrastructure at Leeds. HS is partially supported by the Houston VA HSR&D
Center for Innovations in Quality, Effectiveness and Safety (CIN 13–413) and
the Agency for Health Care Research and Quality (R01HS022087). MT is
funded by a PCORI methods research award (Patient Centered Research on
Outcomes of Diagnostic Testing ME-1503-29245).
Availability of data and materials
All data generated or analysed during this study are included in this published
article and its supplementary information files.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1The Primary Care Unit, Department of Public Health & Primary Care,
University of Cambridge, Cambridge CB1 8RN, UK. 2Department of Family
Medicine, University of Washington, Seattle, USA. 3University of Exeter, St
Luke’s Campus, Exeter EX1 2LU, UK. 4Department of Behavioural Science and
Health, Epidemiology of Cancer Healthcare and Outcomes (ECHO) Research
Group, University College London, London, UK. 5National Institute of Health
Research (NIHR) Leeds In Vitro Diagnostic Cooperative (IVDC), Leeds Centre
for Personalised Medicine and Health, University of Leeds, Leeds, UK.
6Academic Unit of Primary Care, Leeds Institute of Health Sciences, University
of Leeds, Leeds, UK. 7Institute of Health and Society, University of Newcastle,
Sir James Spence Institute, Royal Victoria Infirmary, Newcastle NE1 4LP, UK.
Walter et al. BMC Cancer          (2019) 19:586 Page 10 of 11
8Center for Innovations in Quality, Effectiveness and Safety, Michael E.
DeBakey Veterans Affairs Medical Center and Baylor College of Medicine,
Houston, TX, USA. 9Health Economics Group, University of Exeter, St Luke’s
Campus, Exeter EX1 2LU, Devon, UK. 10Research Centre for Cancer Diagnosis
– CaP, The Research Unit for General Practice and Research Clinic for
Innovative Health Care Delivery, Department of Clinical Medicine, Aarhus
University, Bartholins Alle 2, 8000 Aarhus, Denmark. 11Centre for Cancer
Research and Department of General Practice, University of Melbourne, 10th
floor, Victorian Comprehensive Cancer Centre, 305 Grattan St, Melbourne, VIC
3010, Australia.
Received: 27 August 2018 Accepted: 23 May 2019
References
1. Rubin G, Berendsen A, Crawford SM, Dommett R, Earle C, Emery J, et al. The
expanding role of primary care in cancer control. Lancet Oncol. 2015;16:1231–72.
2. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6:140–6.
3. Lyratzopoulos G, Vedsted P, Singh H. Understanding missed opportunities
for more timely diagnosis of cancer in symptomatic patients after
presentation. Br J Cancer. 2015;112(Suppl 1):84–91.
4. Rubin G, Walter F, Emery J, de Wit N. Reimagining the diagnostic pathway
for gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2018;15:181–8.
5. Phillips KA, Van Bebber S, Issa AM. Diagnostics and biomarker development:
priming the pipeline. Nat Rev Drug Discov. 2006;5:463–9.
6. Usher-Smith JA, Sharp SJ, Griffin SJ. The spectrum effect in tests for risk
prediction, screening, and diagnosis. BMJ. 2016;353:i3139.
7. Pinsky PF, Prorok PC, Kramer BS. Prostate Cancer screening - a perspective
on the current state of the evidence. N Engl J Med. 2017;376:1285–9.
8. Lijmer JG, Leeflang M, Bossuyt PM. Proposals for a phased evaluation of
medical tests. Med Decis Mak. 2009;29:E13–21.
9. Arksey H, O'Malley L. Scoping studies: towards a methodological framework.
Int J Soc Res Methodol. 2005;8:19e31.
10. Colquhoun HL, Levac D, O'Brien KK, Straus S, Tricco AC, Perrier L, et al.
Scoping reviews: time for clarity in definition, methods, and reporting. J Clin
Epidemiol. 2014;67:1291–4.
11. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis
Mak. 1991;11:88–94.
12. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al.
Current methods of the US preventive services task force: a review of the
process. Am J Prev Med. 2001;20:21–35.
13. Gazelle GS, Kessler L, Lee DW, McGinn T, Menzin J, Neumann PJ, et al. A
framework for assessing the value of diagnostic imaging in the era of
comparative effectiveness research. Radiology. 2011;261:692–8.
14. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF,
et al. NCCN task force report: evaluating the clinical utility of tumor markers
in oncology. J Natl Compr Cancer Netw. 2011;9(Suppl 5):1–32 quiz S3.
15. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al.
Phases of biomarker development for early detection of cancer. J Natl
Cancer Inst. 2001;93(14):1054–61.
16. Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ.
Assessing the value of diagnostic tests: a framework for designing and
evaluating trials. BMJ. 2012;344:e686.
17. Horvath AR, Lord SJ, StJohn A, Sandberg S, Cobbaert CM, Lorenz S, et al.
From biomarkers to medical tests: the changing landscape of test
evaluation. Clin Chim Acta. 2014;427:49–57.
18. Thompson M, Weigl B, Fitzpatrick A, Ide N. More than just accuracy: a
novel method to incorporate multiple test attributes in evaluating
diagnostic tests including point of care tests. IEEE J Transl Eng Health
Med. 2016;4:2800208.
19. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al.
The evaluation of genomic applications in practice and prevention (EGAPP)
initiative: methods of the EGAPP working group. Genet Med. 2009;11:3–14.
20. Rosenkotter N, Vondeling H, Blancquaert I, Mekel OC, Kristensen FB, Brand
A. The contribution of health technology assessment, health needs
assessment, and health impact assessment to the assessment and
translation of technologies in the field of public health genomics. Public
Health Genomics. 2011;14:43–52.
21. Rousseau F, Lindsay C, Charland M, Labelle Y, Bergeron J, Blancquaert I, et
al. Development and description of GETT: a genetic testing evidence
tracking tool. Clin Chem Lab Med. 2010;48:1397–407.
22. Sun F, Schoelles KM, Coates VH. Assessing the utility of genetic tests. J
Ambul Care Manage. 2013;36:222–32.
23. Lin JS, Thompson M, Goddard KA, Piper MA, Heneghan C, Whitlock EP.
Evaluating genomic tests from bench to bedside: a practical framework.
BMC Med Inform Decis Mak. 2012;12:117.
24. Singh H, Sittig DF. Advancing the science of measurement of diagnostic
errors in healthcare: the safer dx framework. BMJ Qual Saf. 2015;24:103–10.
25. Price CP, St John A. Anatomy of a value proposition for laboratory
medicine. Clin Chim Acta. 2014;436:104–11.
26. UNION TEPATCOTE. In: OJotE U, editor. Regulation (EU) 2017/746 of the
European Parliament and of the council of 5 April 2017 on in vitro
diagnostic medical devices and repealing directive 98/79/EC and
commission decision 2010/227/EU; 2017. p. L117.
27. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker
research. Nat Rev Cancer. 2005;5(2):142–9.
28. Verbakel JY, Turner PJ, Thompson MJ, Plüddemann A, Price CP, Shinkins B,
et al. Common evidence gaps in point-of-care diagnostic test evaluation: a
review of horizon scan reports. BMJ Open. 2017;7:e015760.
29. Schunemann HJ, Mustafa RA. Decision making about healthcare-related
tests and diagnostic test strategies. Paper 1: a new series on testing to
improve people's health. J Clin Epidemiol. 2017;92:16–7.
30. Patient-Centered Outcomes Research Institute (PCORI). PCORI Methodology
Report 2017. https://www.pcori.org/sites/default/files/PCORI-Methodology-
Report.pdf. Accessed 15 Aug 2018.
31. Strom P, Nordstrom T, Gronberg H, Eklund M. The Stockholm-3 model
for prostate Cancer detection: algorithm update, biomarker contribution,
and reflex test potential. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.
2017.12.028.
32. Cohen JD, Li L, Wang Y, Afsari B, Danilova L, Douville C, et al. Detection and
localization of surgically resectable cancers with a multi-analyte blood test.
Science. 2018;359:926–30.
33. Singh H, Sittig DF. Measuring and improving patient safety through
health information technology: the health IT safety framework. BMJ
Qual Saf. 2016;25:226–32.
34. Hofmann B, Welch HG. New diagnostic tests: more harm than good. BMJ.
2017;358:j3314.
35. Mustafa RA, Wiercioch W, Cheung A, Prediger B, Brozek J, Bossuyt P, et al.
Decision making about healthcare-related tests and diagnostic test
strategies. Paper 2: a review of methodological and practical challenges. J
Clin Epidemiol. 2017;92:18–28.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Walter et al. BMC Cancer          (2019) 19:586 Page 11 of 11
